journal article·2014-03

Biodistribution and toxicity assessment of europium-doped Gd2O3 nanotubes in mice after intraperitoneal injection

Huifang Liu, Cuimiao Zhang, Yanli Tan, Jianguo Wang, Ke Wang, Yanyan Zhao, Guang Jia, Yingjian Hou, Shuxian Wang, Jinchao Zhang

Journal of Nanoparticle Research· Volume 16· Issue 3
Publisher page

Abstract

In order to evaluate the biodistribution and toxicity of europium-doped Gd2O3 nanotubes, we synthesized Gd2O3:Eu3+ nanotubes via a simple wet-chemical route at ambient pressure. The as-obtained Gd2O3:Eu3+ sample is composed of uniform and well-dispersed nanotubes. The diameters and lengths of the nanotubes are about 50 and 300 nm, respectively. All mice of the experimental groups were administered by intraperitoneal injection everyday over a period of 60 days at doses ranging from 1.25 to 125 mg/kg. Haematological and biochemical parameters and histopathology were examined, and the biodistribution of Gd element in different organs was analyzed. The results indicate that the spleen shows significant higher coefficient than the control, and other organs have no obvious difference from the control in the middle-dose and high-dose groups. There was no significant difference in the blood-elements between the control group and the experimental groups, and no significant change of all parameters can be observed in both low-dose and middle-dose groups. However, in the high-dose group, the ALT, AST, the ratio of AST/ALT, UA, LDH, and HBDH levels was increased significantly in comparison with the control group. The pathology results show that the ischemia of myocardial cell, hemorrhage of lung tissue, hepatocyte necrosis, congestion of renal interstitium, mesangial cell proliferation, and congestion of spleen sinus were induced by high-dose Gd2O3:Eu3+ nanotubes. Biodistribution experiment exhibits that Gd mainly accumulates in spleen, lung, and liver. Therefore, it can be concluded that high-dose Gd2O3:Eu3+ nanotubes were toxic, but low-dose and middle-dose groups did not show significant toxicity. The results provide novel toxicology data of Gd2O3:Eu3+ nanotubes and may be helpful for more rational applications of Gd-based compounds in the future.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Graphene and Nanomaterials Applications · Nanoparticles: synthesis and applications · Carbon and Quantum Dots Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (33)

Show source-provided references
1. Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P (2008) Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 158:273–28010.1111/j.1365-2133.2007.08335.x ↗
2. Aillon KL, Xie Y, El-Gendy N, Berkland CJ, Forrest ML (2009) Effects of nanomaterial physicochemical properties on in vivo toxicity. Adv Drug Deliv Rev 61:457–46610.1016/j.addr.2009.03.010 ↗
3. Chen C, Xing G, Wang J, Zhao Y, Li B, Tang J, Jia G, Wang T, Sun J, Xing L, Yuan H, Gao Y, Meng H, Chen Z, Zhao F, Chai Z, Fang X (2005) Multihydroxylated [Gd@C82(OH)22]n nanoparticles: antineoplastic activity of high efficiency and low toxicity. Nano Lett 5:2050–205710.1021/nl051624b ↗
4. Cowper SE, Rabach M, Girardi M (2008) Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol 66:191–19910.1016/j.ejrad.2008.01.016 ↗
5. Fischer HC, Chan WC (2007) Nanotoxicity: the growing need for in vivo study. Curr Opin Biotechnol 18:565–57110.1016/j.copbio.2007.11.008 ↗
6. Hemmer E, Takeshita H, Yamano T, Fujiki T, Kohl Y, Löw K, Venkatachalam N, Hyodo H, Kishimoto H, Soga K (2012) In vitro and in vivo investigations of upconversion and NIR emitting Gd2O3:Er3+, Yb3+ nanostructures for biomedical applications. J Mater Sci Mater Med 23:2399–241210.1007/s10856-012-4671-x ↗
7. Hirst SM, Karakoti A, Singh S, Self W, Tyler R, Seal S, Reilly CM (2013) Bio-distribution and in vivo antioxidant effects of cerium oxide nanoparticles in mice. Environ Toxicol 28:107–11810.1002/tox.20704 ↗
8. Idée JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C (2006) Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 20:563–57610.1111/j.1472-8206.2006.00447.x ↗
9. Jia G, Liu K, Zheng Y, Song Y, Yang M, You H (2009) Highly uniform Gd(OH)3 and Gd2O3:Eu3+ nanotubes: facile synthesis and luminescence properties. J Phys Chem C 113:6050–605510.1021/jp9002164 ↗
10. Krug HF, Wick P (2011) Nanotoxicology: an interdisciplinary challenge. Anqew Chem Int Ed Enql 50:1260–127810.1002/anie.201001037 ↗
11. Le UM, Cui Z (2006) Long-circulating gadolinium-encapsulated liposomes for potential application in tumor neutron capture therapy. Int J Pharm 312:105–11210.1016/j.ijpharm.2006.01.002 ↗
12. Magda D, Miller RA (2006) Motexafin gadolinium: a novel redox active drug for cancer therapy. Semin Cancer Biol 16:466–47610.1016/j.semcancer.2006.09.002 ↗
13. Nakamura Y, Tsumura Y, Tonoqai Y, Shibata T, Ito Y (1997) Differences in behavior among the chlorides of seven rare earth elements administered intravenously to rats. Fundam Appl Toxicol 37:106–11610.1006/faat.1997.2322 ↗
14. Palasz A, Czekaj P (2000) Toxicological and cytophysiological aspects of lanthanides action. Acta Biochim Pol 47:1107–111410.18388/abp.2000_3963 ↗
15. Patra CR, Abdel Moneim SS, Wang E, Dutta S, Patra S, Eshed M, Mukherjee P, Gedanken A, Shah VH, Mukhopadhyay D (2009) In vivo toxicity studies of europium hydroxide nanorods in mice. Toxicol Appl Pharmacol 240:88–9810.1016/j.taap.2009.07.009 ↗
16. Pradhan AK, Zhang K, Bahoura M, Pradhan J, Ravichandran P, Gopikrishnan R, Ramesh GT (2011) Synthesis, characterization, toxicity of nanomaterials for biomedical applications. In: Anthony L (ed) Biomedical engineering, trends in materials science. Intech, Rijeka, pp 348–374
17. Rada S, Rada M, Culea E (2011) Structural and optical properties of the gadolinium–lead–germanate glasses. J Non-Cryst Solids 357:62–6610.1016/j.jnoncrysol.2010.10.013 ↗
18. Radford IR (2000) Gd-Tex Pharmacyclics Inc. Curr Opin Investiq Drugs 1:524–528
19. Samet JM, Dominici F, Curriero FC, Coursac I, Zeger SL (2000) Fine particulate air pollution and mortality in 20 U.S. cities, 1987–1994. N Engl J Med 343:1742–174910.1056/NEJM200012143432401 ↗
20. Sarkar A, Das J, Manna P, Sil PC (2011) Nano-copper induces oxidative stress and apoptosis in kidney via both extrinsic and intrinsic pathways. Toxicology 290:208–21710.1016/j.tox.2011.09.086 ↗
21. Sessler JL, Miller RA (2000) Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem Pharmacol 59:733–73910.1016/S0006-2952(99)00314-7 ↗
22. Sharma P, Brown SC, Walter G, Santra S, Scott E, Ichiwaka H, Fukumori Y, Moudgil BM (2007) Gd nanoparticulates: from magnetic resonance imaging to neutron capture therapy. Adv Powder Technol 18:663–69810.1163/156855207782515030 ↗
23. Sherry AD, Caravan P, Lenkinski RE (2009) Primer on gadolinium chemistry. J Magn Reson Imaging 30:1240–124810.1002/jmri.21966 ↗
24. Sung JH, Ji JH, Park JD, Yoon JU, Kim DS, Jeon KS, Song MY, Jeong J, Han BS, Han JH, Chung YH, Chang HK, Lee JH, Cho MH, Kelman BJ, Yu IJ (2009) Subchronic inhalation toxicity of silver nanoparticles. Toxicol Sci 108:452–46110.1093/toxsci/kfn246 ↗
25. Thomsen HS (2004) Gadolinium-based contrast media may be nephrotoxic even at approved doses. Eur Radiol 14:1654–1656
26. Von Klot S, Wolke G, Tuch T, Heinrich J, Dockery DW, Schwartz J, Kreyling WG, Wichmann HE, Peters A (2002) Increased asthma medication use in association with ambient fine and ultrafine particles. Eur Respir J 20:691–70210.1183/09031936.02.01402001 ↗
27. Wang H, Wang J, Deng X, Sun H, Shi Z, Gu Z, Liu Y, Zhao Y (2004) Biodistribution of carbon single-wall carbon nanotubes in mice. J Nanosci Nanotechnol 4:1019–102410.1166/jnn.2004.146 ↗
28. Wang B, Feng WY, Wang TC, Jia G, Wang M, Shi JW, Zhang F, Zhao YL, Chai ZF (2005) Acute toxicity of nano- and micro-scale zinc powder in healthy adult mice. Toxicol Lett 161:115–12310.1016/j.toxlet.2005.08.007 ↗
29. Wang J, Chen C, Li B, Yu H, Zhao Y, Sun J, Li Y, Xing G, Yuan H, Tang J, Chen Z, Meng H, Gao Y, Ye C, Chai Z, Zhu C, Ma B, Fang X, Wan L (2006) Antioxidative function and biodistribution of [Gd@C82(OH)22]n nanoparticles in tumor-bearing mice. Biochem Pharmacol 71:872–88110.1016/j.bcp.2005.12.001 ↗
30. Wang J, Zhou G, Chen C, Yu H, Wang T, Ma Y, Jia G, Gao Y, Li B, Sun J, Li Y, Jiao F, Zhao Y, Chai Z (2007) Acute toxicity and biodistribution of different sized titanium dioxide particles in mice after oral administration. Toxicol Lett 168:176–18510.1016/j.toxlet.2006.12.001 ↗
31. Wang B, Feng W, Wang M, Wang T, Gu Y, Zhu M, Ouyang H, Shi J, Zhang F, Zhao Y, Chai Z, Wang H, Wang J (2008) Acute toxicological impact of nano- and submicro-scaled zinc oxide powder on healthy adult mice. J Nanopart Res 10:263–27610.1007/s11051-007-9245-3 ↗
32. Yokel RA, Au TC, MacPhail R, Hardas SS, Butterfield DA, Sultana R, Goodman M, Tseng MT, Dan M, Haghnazar H, Unrine JM, Graham UM, Wu P, Grulke EA (2009) Distribution, elimination, and biopersistence to 90 days of a systemically introduced 30 nm ceria-engineered nanomaterial in rats. Toxicol Sci 127:256–26810.1093/toxsci/kfs067 ↗
33. Zhang K, Holloway T, Bahoura M, Pradhan AK, Prabakaran R, Pradhan J, Smith S, Hall JC, Ramesh GT, Sahu DR, Huang JL (2009) Europium doped Gd2O3 and FeCo nanoparticles for biomedical application. Proc of SPIE 7291:729104–72911010.1117/12.817306 ↗